Karyopharm Therapeutics affirms FY2026 sales guidance at $130M-$150M
Karyopharm Therapeutics (NASDAQ: KPTI) affirms FY2026 sales guidance of $130.000 million-$150.000 million versus a $133.736 million estimate, keeping the same range.
Karyopharm Therapeutics (NASDAQ: KPTI ) affirms FY2026 sales outlook from $130.000 million-$150.000 million to $130.000 million-$150.000 million vs $133.736 million estimate.